To evaluate the relationship between activin pathway engagement and stages of severe disease progression, we examined the levels of activin A and B and their pathway marker FLRG in sera from COVID-19 hospitalized pneumonia patients with varying disease severity. This evidence concerns the gene INHBE and COVID-19.